Immediate Infusion Reaction to Intravenous Risankizumab-rzaa but Subsequent Tolerance to Subcutaneous Risankizumab-rzaa
Risankizumab-rzaa (RZA) is a fully human immunoglobulin G monoclonal antibody (Mab) which has fewer immunogenic concerns compared with chimeric Mabs. The pivotal trials of RZA found no significant differences in infusion reactions between drug and placebo. This case illustrates successful transition to subcutaneous RZA following a serious hypersensitivity reaction to intravenous RZA.
Authors
- David Choi (ORCID: https://orcid.org/0000-0002-2453-1784)
- Benjamin D. McDonald (ORCID: https://orcid.org/0000-0003-1308-8788)
- David T. Rubin (ORCID: https://orcid.org/0000-0001-5647-1723)
Institutions
- University of Chicago (US)
Publication Details
- Journal
- ACG Case Reports Journal
- Published
- 2024-11-01
- DOI
- https://doi.org/10.14309/crj.0000000000001546
- Citations
- 2
- Primary Topic
- Drug-Induced Adverse Reactions
- Type
- article
- Field-Weighted Citation Impact
- 0.90
Funders
- Bristol-Myers Squibb
- Eli Lilly and Company
- Janssen Pharmaceuticals